drugset
drugset / Trial / NCT03784222

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

NCT03784222 ↗

Phase 4 Terminated 102 enrolled Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients

Timeline

Start
2019-01-22
Primary completion
2022-11-22
Completion
2022-11-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Blonanserin Small molecule 8 mg Oral
Subject Blonanserin Small molecule 16 mg Oral
Subject Blonanserin Small molecule 24 mg Oral

Indications

CGF1 schizophrenia